Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQRNTG)

• Drug Name: MP-124 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Ischemic stroke	8B11.5Z	Phase 1	[1]
Stroke	8B20	Phase 1	[2]

• Cross-matching ID: TTD Drug ID: DMQRNTG

Molecule-Related Drug Atlas

Drug(s) Targeting Poly [ADP-ribose] polymerase (PARP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Olaparib	DM8QB1D	Ovarian cancer	2C73	Approved	[4]
Rucaparib	DM9PVX8	Ovarian cancer	2C73	Approved	[5]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[6]
MK-4827	DMLYGH4	Ovarian cancer	2C73	Phase 3	[7]
BSI-201	DMM0VO3	Solid tumour/cancer	2A00-2F9Z	Phase 3	[8]
Rubraca rucaparib	DM25TMP	Ovarian cancer	2C73	Phase 3	[9]
ABT-888	DM4HYMS	Breast cancer	2C60-2C65	Phase 3	[7]
INO-1001	DM5L8QT	Brain cancer	2A00	Phase 3	[10]
BGP-15	DMYDM68	Type-2 diabetes	5A11	Phase 2	[11]
BGB-290	DMRO6XT	Ovarian cancer	2C73	Phase 2	[9]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Poly [ADP-ribose] polymerase (PARP)	TTEBCY8	NOUNIPROTAC	Modulator	[3]

References

• [1] MP-124, a novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor, ameliorates ischemic brain damage in a non-human primate model. Brain Res. 2011 Sep 2;1410:122-31.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Company report (Mitsubishi Tanabe Pharma)
• [4] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [5] 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
• [6] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [7] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [8] Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin Cancer Res. 2012 Mar 15;18(6):1655-62.
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] Therapeutic injection of PARP inhibitor INO-1001 preserves cardiac function in porcine myocardial ischemia and reperfusion without reducing infarct size. Shock. 2010 May;33(5):507-12.
• [11] BGP-15, a PARP-inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases. Mol Cell Biochem. 2012 Jun;365(1-2):129-37.